Astrazeneca (AZN) Assets Average (2016 - 2026)

Astrazeneca has reported Assets Average over the past 18 years, most recently at $114.0 billion for Q1 2026.

For Q1 2026, Assets Average rose 8.47% year-over-year to $114.0 billion; the TTM value through Mar 2026 reached $114.0 billion, up 8.47%, while the annual FY2025 figure was $109.1 billion, 109.02% up from the prior year.
Assets Average for Q1 2026 was $114.0 billion at Astrazeneca, roughly flat from $114.3 billion in the prior quarter.
Over five years, Assets Average peaked at $114.3 billion in Q4 2025 and troughed at $48.2 billion in Q4 2023.
A 5-year average of $93.9 billion and a median of $98.4 billion in 2022 define the central range for Assets Average.
Biggest five-year swings in Assets Average: crashed 49.44% in 2023 and later soared 116.76% in 2024.
Year by year, Assets Average stood at $95.3 billion in 2022, then tumbled by 49.44% to $48.2 billion in 2023, then surged by 116.76% to $104.5 billion in 2024, then rose by 9.37% to $114.3 billion in 2025, then fell by 0.19% to $114.0 billion in 2026.
Business Quant data shows Assets Average for AZN at $114.0 billion in Q1 2026, $114.3 billion in Q4 2025, and $113.4 billion in Q3 2025.

Peer Comparison